
Takeda hires Merck senior head as president
pharmafile | November 3, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Takeda, marc princen
Marc Princen has joined Takeda Pharmaceuticals from Merck and is to serve as its corporate officer and president of the firm’s European and Canadian business unit.
Princen will lead Takeda’s business operations in these regions and report directly to Christophe Weber, the pesident and chief operating officer of the Japanese company.
He takes more than 25 years of pharma experience to Takeda, including global roles in a diverse array of functions comprising commercial, marketing, business development and management.
Most recently, Princen served as president of the mid-Europe region at Merck based in Switzerland, and prior to that was president and general manager of its generics wing, as well as the regional president of Eastern Europe, Middle East, and Africa.
Prior to Merck, Princen held a variety of senior leadership positions in the commercial, operational and marketing functions at Schering-Plough.
“I am fully confident that Marc, with his rich set of skills and expertise both broadly across the pharmaceutical industry and specifically in a majority of Takeda’s therapeutic areas, will prove a great asset for Takeda,” says Weber.
Related Content

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …






